Another relevant contribution deriving from RWD was the demonstration of lower efficacy of immunotherapy in BRAF-mutated metastatic melanoma patients relapsing on MAPK inhibition compared with MAPKi naïve patients (144). The gene discussed is BRAF; the disease is metastatic melanoma.